Publications by authors named "Maud Beillat"

Claim this Profile
C
Cost-utility analysis of second line acromegaly treatment in France.
Gérald Raverot, Philippe Chanson, Brigitte Delemer, Delphine Drui, Claire Briet, Maud Beillat

Ann Endocrinol (Paris)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine from Lower-Valent Pneumococcal Conjugate Vaccines in the French Pediatric Population.
Stéphane Fiévez, An Ta, Lucile Bellier, Emmanuelle Blanc, Jessica Y El Khoury, Maud Beillat

Infect Dis Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of delaying PCV20 implementation in France's pediatric national immunization program: A population-based Markov model.
Johnna Perdrizet, Emmanuelle Blanc, Jessica Y El Khoury, Maud Beillat, Ayman Sabra

Infect Dis Now· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Economic Burden of Patients With Haemophilia A and B in France: Analysis of a Nationwide Claims Database.
Laurent Frenzel, Stéphane Bouée, Hervé Lilliu, Véronique Cahoreau, Nicolas Giraud, Maud Beillat

Haemophilia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.
Maud Beillat, Isabelle Durand-Zaleski, France Pirenne, Stève Bénard, Louis Chillotti

Front Public Health· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the public health impact of voxelotor in the management of sickle cell disease in France.
Frédéric Galacteros, Olivier Ethgen, Maud Beillat

PLoS One· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses.
Aus Alzaid, Patricia Ladrón de Guevara, Maud Beillat, Valérie Lehner Martin, Petar Atanasov

Expert Rev Pharmacoecon Outcomes Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Gliclazide-Based Intensive Glucose Control vs. Standard Glucose Control in Type 2 Diabetes Mellitus. An Economic Analysis of the ADVANCE Trial in Vietnam.
Hai-Yen Nguyen-Thi, Nga Tq Nguyen, Nguyen Dang Tu Le, Maud Beillat, Olivier Ethgen

Front Public Health· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Maud Beillat

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Maud Beillat

Int Clin Psychopharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Maud Beillat

Int J Neuropsychopharmacol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis.
Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker

Drugs Context· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials.
Istvan M Majer, Fiona Gaughran, Christophe Sapin, Maud Beillat, Maarten Treur

J Mark Access Health Policy· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Michael Tempest, Christophe Sapin, Maud Beillat, Paul Robinson, Maarten Treur

J Ment Health Policy Econ· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Dieter Naber, Karina Hansen, Carlos Forray, Ross A Baker, Christophe Sapin, Maud Beillat

Schizophr Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada.
Jean Lachaine, Catherine Beauchemin, Karine Mathurin, Dominique Gilbert, Maud Beillat

J Med Econ· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada.
Jean Lachaine, Catherine Beauchemin, Karine Mathurin, Dominique Gilbert, Maud Beillat

BMC Psychiatry· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.
Leonardo Emberti Gialloreti, Monica Merito, Patrizio Pezzotti, Luigi Naldi, Antonio Gatti, Maud Beillat

BMC Infect Dis· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.
Lee Moore, Vanessa Remy, Monique Martin, Maud Beillat, Alistair McGuire

Cost Eff Resour Alloc· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
Gérard de Pouvourville, Anne Solesse, Maud Beillat

Arch Cardiovasc Dis· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis